Hattie Hayes

Where to find members of our editorial board at this year's European Society of Retina Specialists Congress.

Anat Loewenstein, MD, president of EURETINA, announces the EURETINA Innovation Spotlight (EIS) will return on September 3 this year.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration.

At the 2025 EURETINA Congress, keep an eye out for 11 editorial advisory board members from Modern Retina, Ophthalmology Times and Ophthalmology Times Europe.

Retina specialists will celebrate the major anniversary this September in Paris, France.

NICE approves idebenone for Leber hereditary optic neuropathy, offering hope for vision restoration and improved quality of life for patients.

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa.

Baljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery.

New clinical guidance for anterior and posterior uveitis was published by a research team from the University of Bristol.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

Alfredo Sadun, MD, PhD, details a fascinating outcome from a gene therapy in development for Leber hereditary optic neuropathy.

The company shared results from the AAVB-081 clinical program and AAVB-039 preclinical program at ARVO.

According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.

The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.

Abby Markward, MBA, executive director of the ASCRS Foundation and the ASOA, provides a sneak peek of the posterior segment-focused event.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema.

The first session of the 2025 COPHy meeting was titled "Big controversies in retina and beyond in 2025.”

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

The event will include presentations on artificial intelligence, ocular imaging and surgical topics.

ENCELTO is the first and only FDA-approved treatment for MacTel.

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease.